Literature DB >> 27480841

Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition.

Jessica R Wilson1, Nancy J Brown2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27480841      PMCID： PMC4982800          DOI： 10.1161/HYPERTENSIONAHA.116.07884

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  12 in total

1.  Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.

Authors:  Edwin K Jackson; Zaichuan Mi; Stevan P Tofovic; Delbert G Gillespie
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

2.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

3.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

Authors:  William B White; Christopher P Cannon; Simon R Heller; Steven E Nissen; Richard M Bergenstal; George L Bakris; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; William C Cushman; Faiez Zannad
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

4.  Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.

Authors:  Annis Marney; Siri Kunchakarra; Loretta Byrne; Nancy J Brown
Journal:  Hypertension       Date:  2010-08-02       Impact factor: 10.190

5.  Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.

Authors:  William B White; Craig A Wilson; George L Bakris; Richard M Bergenstal; Christopher P Cannon; William C Cushman; Simon K Heller; Cyrus R Mehta; Steven E Nissen; Faiez Zannad; Stuart Kupfer
Journal:  Hypertension       Date:  2016-08-01       Impact factor: 10.190

6.  Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.

Authors:  Faiez Zannad; Christopher P Cannon; William C Cushman; George L Bakris; Venu Menon; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; Hung Lam; William B White
Journal:  Lancet       Date:  2015-03-10       Impact factor: 79.321

7.  Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.

Authors:  Kiwon Ban; M Hossein Noyan-Ashraf; Judith Hoefer; Steffen-Sebastian Bolz; Daniel J Drucker; Mansoor Husain
Journal:  Circulation       Date:  2008-04-21       Impact factor: 29.690

8.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Jennifer B Green; M Angelyn Bethel; Paul W Armstrong; John B Buse; Samuel S Engel; Jyotsna Garg; Robert Josse; Keith D Kaufman; Joerg Koglin; Scott Korn; John M Lachin; Darren K McGuire; Michael J Pencina; Eberhard Standl; Peter P Stein; Shailaja Suryawanshi; Frans Van de Werf; Eric D Peterson; Rury R Holman
Journal:  N Engl J Med       Date:  2015-06-08       Impact factor: 91.245

9.  Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.

Authors:  Jessica K Devin; Mias Pretorius; Hui Nian; Chang Yu; Frederic T Billings; Nancy J Brown
Journal:  Hypertension       Date:  2014-02-10       Impact factor: 10.190

10.  Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.

Authors:  Edwin K Jackson; John H Dubinion; Zaichuan Mi
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-01       Impact factor: 2.557
View more
  3 in total

1.  DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment.

Authors:  Jessica R Wilson; Erica M Garner; Mona Mashayekhi; Scott A Hubers; Claudia E Ramirez Bustamante; Scott Jafarian Kerman; Hui Nian; Cyndya A Shibao; Nancy J Brown
Journal:  Hypertension       Date:  2022-01-20       Impact factor: 9.897

Review 2.  The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials.

Authors:  Eugenie R Lumbers; Sarah J Delforce; Kirsty G Pringle; Gary R Smith
Journal:  Front Med (Lausanne)       Date:  2020-05-22

3.  Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria.

Authors:  Mark E Cooper; Vlado Perkovic; Per-Henrik Groop; Berthold Hocher; Uwe Hehnke; Thomas Meinicke; Audrey Koitka-Weber; Sandra van der Walt; Maximilian von Eynatten
Journal:  J Hypertens       Date:  2019-06       Impact factor: 4.844
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.